$VRNO

Verano Holdings Corp. (VRNO): Results of Operations and Financial Condition

Verano Holdings Corp. (VRNO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 vrno-2026630xexx991.htm EX-99.1 Document Verano Announces Strong Second Quarter 2026 Financial Results Highlighted by $218 Million in Revenue Company delivers third consecutive quarter of revenue gains and improved cash flow from operations driven by organic growth CHIC

Original reporting
Published Aug 5, 2026, 11:13 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 11:34 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$VRNO
Bullish
medium confidence
Mentioned
$VRNO
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VRNOBullishMed
01

Why it matters

Traders can update models using the newly reported revenue, EBITDA, operating cash flow, and the tightened 2026 capex range. The rescheduling confirmation and state expansion items may also influence sentiment, but the quantified financials and guidance are the primary decision inputs.

02

Market read

Fresh quarterly financials plus a capex guidance tightening can drive near-term repricing, especially for investors focused on cash generation and growth funding needs.

03

What to watch

The 1-for-5 reverse split and relatively modest $2M repurchase authorization may not materially change fundamentals; investors may instead scrutinize leverage ($393M net debt) and the credibility of capex-to-growth execution.

Relevance 7/10Novelty 8/10Timing: pre-market today, Aug 5, 2026 (8-K filed and results released)

Background

This is Verano’s SEC Form 8-K (Item 2.02) releasing Q2 2026 financial results and related operational updates, including capital allocation and guidance.

Company-level read

Ticker impact

$VRNOBullishMedium confidence
Context

Verano reports Q2 2026 results with $218M revenue, $51M adjusted EBITDA, $31M operating cash flow, and tightens 2026 capex guidance to $40M-$50M.

Expected impact

Likely supportive for the stock on any earnings-day reaction, with follow-through dependent on whether investors focus on revenue growth, cash flow improvement, or margin compression.

Evidence & confidence

The article is a primary SEC 8-K with quantified results and guidance. It also includes a reverse split and a small buyback authorization, but the most decision-relevant items are the new financials and the capex range update.

Market effects

Adds incremental evidence on multi-state cannabis operators’ ability to grow revenue and improve operating cash flow, while highlighting ongoing margin pressure.

Florida retail expansion and Virginia adult-use rollout timing reinforce state-by-state demand ramp expectations for operators with similar footprints.

Limited direct global spillover, but contributes to the broader US cannabis policy narrative around rescheduling and market access.

Counterpoint

Despite revenue growth, gross margin fell vs the prior-year quarter and the company still reports net losses, so the equity may remain valuation-constrained.

Key entities

  • Verano Holdings Corp.

    Multi-state cannabis operator reporting Q2 2026 results, operating cash flow, and updated 2026 capex guidance.

  • U.S. Drug Enforcement Administration (DEA)

    Applications submitted to register certain state-licensed medical cannabis operations.

  • George Archos

    Founder, Chairman and CEO providing commentary on results and capital markets engagement.

Related articles

$NVOMedAI 8/10

Novo Nordisk A/S Q2 Earnings Call Highlights

Novo Nordisk reported Q2 adjusted sales of DKK 78.5 billion, with obesity care sales up 16% and GLP-1 diabetes up 2%. Adjusted gross margin fell to 78.2% from 82.7% due to lower prices, about DKK 3 billion one-time manufacturing-cost items, and FX. The company raised 2026 outlook to 0% to -6% adjusted sales and operating profit growth. ZEUS ziltivekimab trial missed its primary endpoint (HR 0.99).

$NYTMed

New York Times Q2 Earnings Call Highlights

The New York Times Company (NYSE:NYT) reported Q2 results on its earnings call. Digital-only subscribers rose 13.3% YoY and digital-only ARPU increased 3.1%. First-half free cash flow was about $266M and the company returned about $160M to shareholders. It guided Q3 digital-only subscription revenue up 12% to 15% and digital ad revenue up mid- to high-teens.

$OCMed

Owens Corning Q2 Earnings Call Highlights

Owens Corning (NYSE:OC) said Iran-related net cost impact is expected to be about $40 million in Q3, with roofing the most affected segment. The company reported Q2 liquidity of $1.8 billion and plans to repay $400 million of senior notes in Q3. Full-year capex is about $800 million. Roofing Q2 sales were ~$1.3 billion; insulation revenue rose 4% to $971 million.

$OFRMMedAI 8/10

Once Upon A Farm Q2 Earnings Call Highlights

Once Upon a Farm (NYSE:OFRM) reported Q2 growth, with baby sales up 73% to $41.5M and kid sales up 22% to $43.9M, alongside distribution point expansion. Gross margin fell to 35.9% (down 485 bps). SG&A rose to $36.3M. Net loss was $5M. The company cut FY gross margin outlook to ~40% and expects Q3 similar margins.

$OECMed

Orion Q2 Earnings Call Highlights

Orion (NYSE:OEC) reported Q2 updates on coatings and rubber segments. Specialty profitability was supported by pricing actions amid volatile oil-derived feedstock costs. Rubber adjusted EBITDA fell 61% YoY to $19 million. Orion said working capital added $4 million cash, capex fell to $25 million, and it retained full-year guidance assuming $80/bbl crude. Net debt was $961 million.

$OBDCMed

Blue Owl Capital Q2 Earnings Call Highlights

Blue Owl Capital (NYSE:OBDC) reported Q2 earnings call highlights. Management said PIK income fell to 10.7% of total investment income after a realization reduced PIK exposure. LSI life sciences specialty finance vehicle benefited from ITM Radiopharma repayment. Net leverage fell to 1.11x. NAV declined mainly due to a credit markdown on Loparex. The firm repurchased $35M of shares and raised about $800M unsecured debt.